Capricor Therapeutics (NASDAQ:CAPR) Director Sells $240,928.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the transaction, the director directly owned 7,529 shares of the company’s stock, valued at approximately $240,928. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.03, for a total value of $1,667,397.05.
• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $32.11 on Monday. The stock has a fifty day moving average price of $27.38 and a two-hundred day moving average price of $19.19. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37. The firm has a market capitalization of $1.85 billion, a P/E ratio of -14.21 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, equities research analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Oppenheimer upped their price objective on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. UBS Group set a $50.00 price target on Capricor Therapeutics in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Finally, Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. Farther Finance Advisors LLC acquired a new stake in shares of Capricor Therapeutics during the third quarter worth $28,000. Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics in the third quarter valued at about $36,000. Russell Investments Group Ltd. lifted its stake in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares during the period. ACT Capital Management LLC bought a new position in Capricor Therapeutics during the fourth quarter worth about $43,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth about $59,000. 21.68% of the stock is currently owned by institutional investors.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus.
• Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
• Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
• Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
• Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
• Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.